Search clinical trials for: xolair

Total 145 results

Kari Christine Nadeau, MD PhD
University of California, Los Angeles

Completed

Multi OIT to Test Immune Markers After Minimum Maintenance Dose

Food Allergy

United States
Hoffmann-La Roche

Completed

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps (POLYP 2)

Nasal Polyps | Chronic Rhinosinusitis

Spain, United States, Belgium, France, Poland, Hungary, Finland, Mexico, Russian Federation, Ukraine
Hoffmann-La Roche

Completed

A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps (POLYP 1)

Nasal Polyps | Chronic Rhinosinusitis

Czechia, United States, Portugal, Germany, Canada, Ukraine, Poland, Mexico, Russian Federation, United Kingdom
University of California, San Francisco
University of Chicago

Withdrawn

Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis

Chronic Sinusitis
NYU Langone Health

Terminated

Sputum-derived Cellular Targets After Xolair (Omalizumab)

Asthma

United States
University of New Mexico
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Immune Dysfunction in Allergic Asthma

Asthma

United States
Guy's and St Thomas' NHS Foundation Trust
King's College London; National Institute for Health Research, United Kingdom

Completed

Role of Anti-IgE in Severe Childhood Eczema (ADAPT)

Child | Atopic Dermatitis | Atopic Eczema

United Kingdom
Bernstein Clinical Research Center

Withdrawn

A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

Allergy Induced Asthma
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis

Hypotension | Angioedema | Anaphylaxis | Bronchospasm

United States
Yale University

Completed

Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction

Colon Cancer

United States
Clinica Universidad de Navarra, Universidad de...
Hospital General Universitario Gregorio Marañon; Hospital Clinic of Barcelona; Complejo Hospitalario de Navarra and other collaborators

Completed

Efficacy Study of Omalizumab in Cholinergic Urticaria (CUN-OMAL-UCOL)

Cholinergic Urticaria

Spain
Asthma Inc Clinical Research Center
University of Washington

Completed

Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria

Chronic Idiopathic Urticaria

United States
Mayo Clinic
Genentech, Inc.

Withdrawn

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

Acute Interstitial Nephritis

United States
Boston Children's Hospital
Stanford University

Completed

Xolair Treatment for Milk Allergic Children

Milk Allergy

United States
Caroline Nilsson

Unknown

Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy (FASTX)

Peanut Allergy

Sweden
University of Virginia
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

Asthma

United States
Novartis
Genentech, Inc.; Tanox

Completed

Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

Asthma

Canada, Germany, Spain, Belgium, Switzerland, Israel, Portugal, Greece, Hungary, Poland, Ireland, Norway, Denmark, Sweden, Italy, United Kingdom, Turkey
Selina Gierer, D.O.

Withdrawn

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

Urticaria

United States
McMaster University
Novartis

Completed

Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

Eosinophilic Bronchitis | Steroid and/or Prednisone Dependent Asthma

Canada
Genentech, Inc.

Completed

A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria

Urticaria

United States
University of North Carolina, Chapel Hill
Genentech, Inc.

Completed

Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy (PAIE/Xolair)

Peanut Hypersensitivity

United States
Dana-Farber Cancer Institute
Novartis Pharmaceuticals

Completed

Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization

Drug Allergy

United States
Children's Hospital of The King's Daughters
Novartis; Genentech, Inc.

Completed

A Description of Inflammatory Cell Types In Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy

ALLERGIC ASTHMA
Genentech, Inc.
Novartis

Completed

An Observational Study of the Use and Safety of Xolair® During Pregnancy (EXPECT)

Asthma

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients (MAP-X)

Food Allergy

United States
Kari Christine Nadeau
Children's Hospital of Philadelphia; Icahn School of Medicine at Mount Sinai; University of Washington and other collaborators

Completed

Multi Immunotherapy to Test Tolerance and Xolair (M-TAX)

Food Allergy

United States
Johns Hopkins University
Novartis Pharmaceuticals

Completed

Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils

Allergic Asthma

United States
Hoffmann-La Roche

Completed

A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)

Asthma

United States
Clinica Universidad de Navarra, Universidad de...
Hospital Clinic of Barcelona; Complejo Hospitalario de Navarra; Hospital Universitari... and other collaborators

Completed

Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria

Chronic Urticaria

Spain
Johns Hopkins University
Genentech, Inc.

Terminated

Effect of Anti-IgE in Non-Allergic Asthma

Asthma

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma

Asthma

Germany, United States, India, Korea, Republic of, Poland, Romania, South Africa, France, Hungary, United Kingdom, Israel, Russian Federation, Turkey, Italy, Argentina, Mexico, Canada, Czechia, Finland, Portugal, Slovakia, Singapore, Guatema... and more
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Omalizumab in the Treatment of Peanut Allergy

Peanut Allergy | Food Allergy

United States
Genentech, Inc.

Completed

A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)

Chronic Idiopathic Urticaria
Genentech, Inc.

Completed

Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing (X-PAND)

Allergic Asthma

United States
National Institute of Allergy and Infectious Diseases...

Completed

Omalizumab to Treat Hyper-IgE (Job's) Syndrome

Job's Syndrome | Hyper-IgE Syndrome

United States
Massachusetts General Hospital
Genentech, Inc.

Completed

Subcutaneous Omalizumab for Treatment of Chronic Rhinosinusitis With Nasal Polyposis

Nasal Polyps | Chronic Rhinosinusitis

United States
Genentech, Inc.

Completed

A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) (EXACT)

Asthma
Genentech, Inc.

Completed

The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)

Healthy | Asthma
Genentech, Inc.

Completed

A Study of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma (AERO)

Asthma
National Institute of Allergy and Infectious Diseases...
Inner-City Asthma Consortium

Completed

Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (PROSE)

Asthma

United States
Genentech, Inc.

Completed

A Study of Xolair to Evaluate Effectiveness and Long-Term Safety in Patients With Moderate to Severe Asthma

Asthma
Johns Hopkins University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Effect of Omalizumab on Responses to Cat Allergen Challenge

Allergic Rhinitis

United States
Charite University, Berlin, Germany
Novartis Pharmaceuticals

Completed

Cold Urticaria Treatment With Xolair (CUTEX)

Cold Contact Urticaria

Germany
Novartis Pharmaceuticals

Completed

Efficacy/ Safety of Omalizumab in Patients With Seasonal Allergic Asthma and Seasonal Allergic Rhinoconjunctivitis

Allergic Asthma

Germany
National Jewish Health
Novartis

Withdrawn

Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels

Pulmonary Disease, Chronic Obstructive

United States
National Institute of Allergy and Infectious Diseases...
Inner-City Asthma Consortium

Completed

Inner-City Anti-IgE Therapy for Asthma (ICATA)

Asthma

United States
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Completed

Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies

Hypersensitivity | Allergy | Rhinitis | Hay Fever

United States
Ajou University School of Medicine

Unknown

Effects of Omalizumab Compared to Non-Omalizumab Treatment in Asthma Patients

Asthma
Novartis

Completed

A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab) in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy

Asthma

Canada
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients

Chronic Spontaneous Uriticaria

Korea, Republic of, Japan

Search clinical trials for: xolair

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations